In Vitro Diagnostics Market (Technology Type: Point-of-care, Molecular Diagnostics, Immunoassays, Clinical Chemistry, Whole Blood Glucose Monitoring, Hematology, Clinical Microbiology, Coagulation & Hemostasis, and Others; Application: Drug Testing, Infectious Diseases, Oncology, Metabolic Diseases, Autoimmune Diseases, and Others; and End-user: Diagnostic Laboratories, Hospitals, Academic & Research Centers, Home Care, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2030

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global In Vitro Diagnostics Market

4. Market Overview

    4.1. Introduction

        4.1.1. Application Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global In Vitro Diagnostics Market Analysis and Forecast, 2017–2030

        4.4.1. Market Revenue Projections (US$ Mn)

        4.4.2. Market Volume/Unit Shipments Projections

    4.5. Porter’s Five Force Analysis

5. Key Insights

    5.1. Key Mergers and Acquisition

    5.2. Key Success Factor for Top 3 Players

    5.3. Regulatory Scenario

    5.4. Technology Assessment

6. Global In Vitro Diagnostics Market Analysis and Forecast, by Application

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value & Volume Forecast, by Application, 2017–2030

        6.3.1. Drug Testing

        6.3.2. Infectious Diseases

        6.3.3. Oncology

        6.3.4. Metabolic Diseases

        6.3.5. Autoimmune Diseases

        6.3.6. Others

    6.4. Market Attractiveness Analysis, by Application

7. Global In Vitro Diagnostics Market Analysis and Forecast, by End-user  

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value & Volume Forecast, by End-user, 2017–2030

        7.3.1. Diagnostic Laboratories

        7.3.2. Hospitals

        7.3.3. Academic & Research Centers

        7.3.4. Home Care

        7.3.5. Others

    7.4. Market Attractiveness Analysis, by End-user  

8. Global In Vitro Diagnostics Market Analysis and Forecast, by Technology Type

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Market Value & Volume Forecast, by Technology Type, 2017–2030

        8.3.1. Point-of-care

        8.3.2. Molecular Diagnostics

        8.3.3. Immunoassays

        8.3.4. Clinical Chemistry

        8.3.5. Whole Blood Glucose Monitoring

        8.3.6. Hematology

        8.3.7. Clinical Microbiology

        8.3.8. Coagulation & Hemostasis

        8.3.9. Others

    8.4. Market Attractiveness Analysis, by Technology Type

9. Global In Vitro Diagnostics Market Analysis and Forecast, by Region

    9.1. Key Findings

    9.2. Market Value & Volume Forecast, by Region

        9.2.1. North America

        9.2.2. Europe

        9.2.3. Asia Pacific

        9.2.4. Latin America

        9.2.5. Middle East & Africa

    9.3. Market Attractiveness Analysis, by Region

10. North America In Vitro Diagnostics Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value & Volume Forecast, by Application, 2017–2030

        10.2.1. Drug Testing

        10.2.2. Infectious Diseases

        10.2.3. Oncology

        10.2.4. Metabolic Diseases

        10.2.5. Autoimmune Diseases

        10.2.6. Others

    10.3. Market Value & Volume Forecast, by End-user, 2017–2030

        10.3.1. Diagnostic Laboratories

        10.3.2. Hospitals

        10.3.3. Academic & Research Centers

        10.3.4. Home Care

        10.3.5. Others

    10.4. Market Value & Volume Forecast, by Technology Type, 2017–2030

        10.4.1. Point-of-care

        10.4.2. Molecular Diagnostics

        10.4.3. Immunoassays

        10.4.4. Clinical Chemistry

        10.4.5. Whole Blood Glucose Monitoring

        10.4.6. Hematology

        10.4.7. Clinical Microbiology

        10.4.8. Coagulation & Hemostasis

        10.4.9. Others

    10.5. Market Value & Volume Forecast, by Country, 2017–2030

        10.5.1. U.S.

        10.5.2. Canada

    10.6. Market Attractiveness Analysis

        10.6.1. By Application

        10.6.2. By End-user  

        10.6.3. By Technology Type

        10.6.4. By Country

11. Europe In Vitro Diagnostics Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value & Volume Forecast, by Application, 2017–2030

        11.2.1. Drug Testing

        11.2.2. Infectious Diseases

        11.2.3. Oncology

        11.2.4. Metabolic Diseases

        11.2.5. Autoimmune Diseases

        11.2.6. Others

    11.3. Market Value & Volume Forecast, by End-user, 2017–2030

        11.3.1. Diagnostic Laboratories

        11.3.2. Hospitals

        11.3.3. Academic & Research Centers

        11.3.4. Home Care

        11.3.5. Others

    11.4. Market Value & Volume Forecast, by Technology Type, 2017–2030

        11.4.1. Point-of-care

        11.4.2. Molecular Diagnostics

        11.4.3. Immunoassays

        11.4.4. Clinical Chemistry

        11.4.5. Whole Blood Glucose Monitoring

        11.4.6. Hematology

        11.4.7. Clinical Microbiology

        11.4.8. Coagulation & Hemostasis

        11.4.9. Others

    11.5. Market Value & Volume Forecast, by Country/Sub-region, 2017–2030

        11.5.1. Germany

        11.5.2. U.K.

        11.5.3. France

        11.5.4. Spain

        11.5.5. Italy

        11.5.6. Rest of Europe

    11.6. Market Attractiveness Analysis

        11.6.1. By Application

        11.6.2. By End-user  

        11.6.3. By Technology Type

        11.6.4. By Country/Sub-region

12. Asia Pacific In Vitro Diagnostics Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value & Volume Forecast, by Application, 2017–2030

        12.2.1. Drug Testing

        12.2.2. Infectious Diseases

        12.2.3. Oncology

        12.2.4. Metabolic Diseases

        12.2.5. Autoimmune Diseases

        12.2.6. Others

    12.3. Market Value & Volume Forecast, by End-user, 2017–2030

        12.3.1. Diagnostic Laboratories

        12.3.2. Hospitals

        12.3.3. Academic & Research Centers

        12.3.4. Home Care

        12.3.5. Others

    12.4. Market Value & Volume Forecast, by Technology Type, 2017–2030

        12.4.1. Point-of-care

        12.4.2. Molecular Diagnostics

        12.4.3. Immunoassays

        12.4.4. Clinical Chemistry

        12.4.5. Whole Blood Glucose Monitoring

        12.4.6. Hematology

        12.4.7. Clinical Microbiology

        12.4.8. Coagulation & Hemostasis

        12.4.9. Others

    12.5. Market Value & Volume Forecast, by Country/Sub-region, 2017–2030

        12.5.1. China

        12.5.2. Japan

        12.5.3. India

        12.5.4. Australia & New Zealand

        12.5.5. Rest of Asia Pacific

    12.6. Market Attractiveness Analysis

        12.6.1. By Application

        12.6.2. By End-user  

        12.6.3. By Technology Type

        12.6.4. By Country/Sub-region

13. Latin America In Vitro Diagnostics Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value & Volume Forecast, by Application, 2017–2030

        13.2.1. Drug Testing

        13.2.2. Infectious Diseases

        13.2.3. Oncology

        13.2.4. Metabolic Diseases

        13.2.5. Autoimmune Diseases

        13.2.6. Others

    13.3. Market Value & Volume Forecast, by End-user, 2017–2030

        13.3.1. Diagnostic Laboratories

        13.3.2. Hospitals

        13.3.3. Academic & Research Centers

        13.3.4. Home Care

        13.3.5. Others

    13.4. Market Value & Volume Forecast, by Technology Type, 2017–2030

        13.4.1. Point-of-care

        13.4.2. Molecular Diagnostics

        13.4.3. Immunoassays

        13.4.4. Clinical Chemistry

        13.4.5. Whole Blood Glucose Monitoring

        13.4.6. Hematology

        13.4.7. Clinical Microbiology

        13.4.8. Coagulation & Hemostasis

        13.4.9. Others

    13.5. Market Value & Volume Forecast, by Country/Sub-region, 2017–2030

        13.5.1. Brazil

        13.5.2. Mexico

        13.5.3. Rest of Latin America

    13.6. Market Attractiveness Analysis

        13.6.1. By Application

        13.6.2. By End-user  

        13.6.3. By Technology Type

        13.6.4. By Country/Sub-region

14. Middle East & Africa In Vitro Diagnostics Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Market Value & Volume Forecast, by Application, 2017–2030

        14.2.1. Drug Testing

        14.2.2. Infectious Diseases

        14.2.3. Oncology

        14.2.4. Metabolic Diseases

        14.2.5. Autoimmune Diseases

        14.2.6. Others

    14.3. Market Value & Volume Forecast, by End-user, 2017–2030

        14.3.1. Diagnostic Laboratories

        14.3.2. Hospitals

        14.3.3. Academic & Research Centers

        14.3.4. Home Care

        14.3.5. Others

    14.4. Market Value & Volume Forecast, by Technology Type, 2017–2030

        14.4.1. Point-of-care

        14.4.2. Molecular Diagnostics

        14.4.3. Immunoassays

        14.4.4. Clinical Chemistry

        14.4.5. Whole Blood Glucose Monitoring

        14.4.6. Hematology

        14.4.7. Clinical Microbiology

        14.4.8. Coagulation & Hemostasis

        14.4.9. Others

    14.5. Market Value & Volume Forecast, by Country/Sub-region, 2017–2030

        14.5.1. GCC Countries

        14.5.2. South Africa

        14.5.3. Rest of Middle East & Africa

    14.6. Market Attractiveness Analysis

        14.6.1. By Application

        14.6.2. By End-user  

        14.6.3. By Technology Type

        14.6.4. By Country/Sub-region

15. Competition Landscape

    15.1. Market Player - Competition Matrix (by tier and size of companies)

    15.2. Market Share Analysis, by Company, 2020

    15.3. Market Footprint Analysis

        15.3.1. By Region

        15.3.2. By Application Type

    15.4. Competitive Business Strategies

    15.5. Company Profiles

        15.5.1. Competition Matrix

            15.5.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.5.1.2. Product Portfolio

            15.5.1.3. SWOT Analysis

            15.5.1.4. Strategic Overview

        15.5.2. F. Hoffmann-La Roche Ltd.

            15.5.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.5.2.2. Product Portfolio

            15.5.2.3. SWOT Analysis

            15.5.2.4. Strategic Overview

        15.5.3. Danaher

            15.5.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.5.3.2. Product Portfolio

            15.5.3.3. SWOT Analysis

            15.5.3.4. Strategic Overview

        15.5.4. Siemens Healthineers

            15.5.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.5.4.2. Product Portfolio

            15.5.4.3. SWOT Analysis

            15.5.4.4. Strategic Overview

        15.5.5. bioMérieux SA

            15.5.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.5.5.2. Product Portfolio

            15.5.5.3. SWOT Analysis

            15.5.5.4. Strategic Overview

        15.5.6. Abbott

            15.5.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.5.6.2. Product Portfolio

            15.5.6.3. SWOT Analysis

            15.5.6.4. Strategic Overview

        15.5.7. Diasorin

            15.5.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.5.7.2. Product Portfolio

            15.5.7.3. SWOT Analysis

            15.5.7.4. Strategic Overview

        15.5.8. Meridian Bioscience, Inc.

            15.5.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.5.8.2. Product Portfolio

            15.5.8.3. SWOT Analysis

            15.5.8.4. Strategic Overview

        15.5.9. Ortho-Clinical Diagnostics, Inc.

            15.5.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.5.9.2. Product Portfolio

            15.5.9.3. SWOT Analysis

            15.5.9.4. Strategic Overview

        15.5.10. Thermo Fisher Scientific, Inc.

            15.5.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.5.10.2. Product Portfolio

            15.5.10.3. SWOT Analysis

            15.5.10.4. Strategic Overview

        15.5.11. Sysmex Corporation

            15.5.11.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.5.11.2. Product Portfolio

            15.5.11.3. SWOT Analysis

            15.5.11.4. Strategic Overview

        15.5.12. Other Prominent Players

            15.5.12.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.5.12.2. Product Portfolio

            15.5.12.3. SWOT Analysis

            15.5.12.4. Strategic Overview